This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

      

You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site.

Continue

Go back

Access free resources

Order resources to support your patients including, samples, demo devices, leaflets plus more.

See what's available

Educational webinars

Join your peers and healthcare experts at live webinars run by GSK.

Webinars on demand

Catch up on Asthma & COPD video webinars anytime from the comfort of your own office.

Access free resources

Order resources to support your patients including, samples, demo devices, leaflets plus more.

See what's available

Educational webinars

Join your peers and healthcare experts at live webinars run by GSK.

What's coming up?

Webinars on demand

Catch up on Asthma & COPD video webinars anytime from the comfort of your own office.

Explore more

Respiratory Products

Relvar Ellipta

25% more patients improve asthma control vs. other ICS/LABAs in everyday clinical practice. 1

Trelegy▼ Ellipta

Discover more about the only once daily COPD single inhaler triple therapy available in Ireland. 2

Anoro▼ Ellipta

Discover more about the only once-daily LAMA/LABA to demonstrate superiority in lung function within the class. 3

Incruse Ellipta

Incruse Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD 4

Respiratory Products

Relvar Ellipta

25% more patients improve asthma control vs. other ICS/LABAs in everyday clinical practice. 1

Trelegy▼ Ellipta

Discover more about the only once daily COPD single inhaler triple therapy available in Ireland. 2

Anoro▼ Ellipta

Discover more about the only once-daily LAMA/LABA to demonstrate superiority in lung function within the class. 3

Incruse Ellipta

Incruse Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD 4

More Information

Dovato (dolutegravir and lamivudine)

GEMINI 144 week and TANGO 96 week delivered insightful data on Dovato’s Efficacy, Tolerability, Drug-to-Drug Interactions, Resistance and Metabolic Outcomes. Learn more about why Dovato is a robust option for your patients. 5 6

Explore the data

Prescribing information

Zejula tile

Zejula (niraparib) patient booklet available to order online

This Zejula patient booklet has been developed to provide information on some of the questions patients prescribed Zejula may have and helps to support them on their treatment journey. 7

Order today

Prescribing information

Using dual therapy or triple therapy for your patients?

The IMPACT trial was the first trial to assess the efficacy and safety of single inhaler Triple Therapy TRELEGY▼ Ellipta vs. an ICS/LABA (FF/VI 92/22 mcg) and a LAMA/LABA (UMEC/VI). 8

Explore the IMPACT data

Prescribing information

Stay Informed

Sign up to receive email alerts from GSK including important supply updates, new product information and events we are running.

Register Now

Abbreviations

FEV1, forced expiratory volume in one second; FF, fluticasone furoate; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; OD, once-daily; UMEC, umeclidinium; VI, vilanterol

References:

  1. Woodcock A et al. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel-group, randomised controlled trial. Lancet 2017;290:22247-2255.
  2. Trelegy Ellipta SmPC 2020. Available at www.medicines.ie. Last accessed July 2021
  3. Anoro Ellipta Summary of Product Characteristics. Available from: medicines.ie. Accessed July 2021
  4. Incruse Ellipta Summary of Product Characteristics. Available from: medicines.ie. Accessed July 2021
  5. Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naïve adults with HIV-1 infection—3-year results from the GEMINI studies. Presented at: HIV Glasgow 2020; October 5-8, 2020; Virtual. Poster P018.
  6. van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority TANGO study. Clin Infect Dis. 2020. doi:10.1093/cid/ciz1243
  7. Zejula Summary of Product Characteristics. Available from: www.medicines.ie. Accessed July 2021
  8. Lipson DA et al. N Engl J Med 2018; 378:1671–1680.

 

Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trade marks are owned by or licensed to the GSK group of companies.